the aid library

LIST OPTIONS

Filter

13030

UN Multi-Sector Response Plan to COVID-19 for Mozambique

UNCT Mozambique (2020) CC

Mozambique registered its first COVID-19 case on 22 March 2020 and since then numbers have steadily grown over the following three months with cases now reported in all provinces. In response, a level 3 State of emergency was enacted on 1 April 2020 and has been extended until 29 July 2020, with mea... more

National Comprehensive HIV Prevention, Care, and Treatment Training for Pharmacy Professionals. Participant Manual

Ministry of Health, Federal Democratic Republic of Ethiopia Ministry of Health, Federal Democratic Republic of Ethiopia (2018) CC

In line with its decentralization principle, the Ethiopian Health Policy has achieved great progress in improving access to comprehensive HIV/AIDS services to the majority of the population. Both quality and coverage of services have improved significantlysince the initiation... more

Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2021

World Health Organization WHO (2021) C_WHO

9 June 2021 Since its launch, GLASS has expanded in scope and coverage and as of May 2021, 109 countries and territories worldwide have enrolled in GLASS. A key new component in GLASS is the inclusion of antimicrobial consumption (AMC) surveillance at the national level highlighted in this fourth G... more

External Link

Catholic Social Teaching

Caritas Australia (2021) CC

With human dignity at its centre, a holistic approach to development founded on the principles of CST, is what Pope Paul VI called ‘authentic development’. Explore the Catholic Social Teaching principles and how they guide our work

Download (274)

View PDF (210)

Polio transition planning and polio post-certification: Report by the Director-General

World Health Organization WHO (2022) C_WHO

The Executive Board at its 150th session noted an earlier version of this report.1 The present report provides an update on the implementation of the Strategic Action Plan on Polio Transition (2018–2023)2 at the start of 2022, within the context of the coronavirus disease (COVID-19) pandemic.

Download (132)

View PDF (185)

Learn more about monkeypox as we record first confirmed case in SA

Saphra (2022) CC

South Africa has recorded its first case of monkeypox today, 23 June 2022. The Minister of Health Dr. Joe Phaahla explained that he received a report from the National Health Laboratory Services’ CEO that they have confirmed through laboratory tests the first case of monkeypox in South Africa. ... more

External Link

Chagas Clinical Research Platform Newsletter

Drugs for Neglected Diseases Initiative DNDi Latin America (2022) CC

To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f... more

Download (142)

View PDF (164)

Target product profile for a point-of-care diagnostic test for dermal leishmaniases - Control of Neglected Tropical Diseases

World Health Organization WHO (2022) C_WHO

Localized cutaneous leishmaniasis and its evolving forms (diffuse cutaneous leishmaniasis, mucosal leishmaniasis and cutaneous leishmaniasis recidivans), together with the sequela of visceral leishmaniasis (post-kala-azar dermal leishmaniasis), account for about one million cases of dermal leishmani... more

External Link

Snakebite envenoming: Snakebite Information and Data Platform

World Health Organization WHO (2023) C_WHO

As part of its 2019–2030 global strategy for the prevention and control of snakebite envenoming, WHO is launching a new Snakebite Information and Data Platform. This is the result of collaboration between the Departments of Control of Neglected Tropical Diseases (WHO/NTD) and Data Delivery for Imp... more

Nigeria: reducing the indirect causes of maternal morbidity and mortality: the RICOM3 Project

World Health Organisation (WHO) (2023) C_WHO

Nigeria reported its first case of COVID-19 at the end of February 2020 and subsequently experienced four waves, with peaks in June 2020 and January, August and December 2021. The COVID-19 pandemic severely impacted the economy of Nigeria and caused disruption of health services nationwide. During... more

External Link

Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease

Rassi A., Dias J.C.P., Marin-Neto J.a. Heart (2009) C2

A century after its discovery, Chagas' disease still represents a major public health challenge in Latin America. Moreover, because of growing population movements, an increasing number of cases of imported Chagas' disease have now been detected in non-endemic areas, such as North America and some E... more

Download (95)

View PDF (111)

ACT-A - Urgent Priorities & Financing Requirements at 10 November 2020

World Health Organization (WHO), The Global Fund, Gavi et al. World Health Organization (WHO) (2020) CC

Six months after its launch on 24 April, the Access to COVID-19 Tools (ACT) Accelerator has already delivered concrete results in speeding up the development of new therapeutics, diagnostics, and vaccines. Now mid-way through the scale-up phase, the tools we need to fundamentally change the course o... more

External Link

Tool for Promoting Culturally Safe Childbirth: Basic Manual

Pan American Health Organization PAHO (2023) CC

This manual and its Excel tool are under revision. The revised edition will be published soon.

Download (211)

View PDF (193)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Renewable energy solutions improve children’s health and wellbeing in Malawi

Unicef (2021) C_UNICEF

UNICEF Malawi and its partners are prioritizing renewable energy solutions for children and communities across the country to access clean and affordable electricity, with a focus on hard-to-reach, rural communities unable to access the national electricity grid.

Download (1088)

View PDF (3049)

DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended

Médecins sans Frontières (2016) C_WHO

4th edition. This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s... more

External Link

The BMJ- Ebola Virus Infection

British Medical Journal (2018) CC

The BMJ has made all of its articles referring to the Ebola outbreak free to access. The content includes latest guidance for healthcare workers, which 'will continue to update healthcare workers, outside of west Africa, with the latest guidance from the UK's Health Protection Agency and the US Cen... more

External Link

H2P Community Planning and Response Curriculum. District and Community Leaders

Humanitarian Pandemic Preparedness (H2P) Initiative USAID; ICRC; CoreGroup; et al. (2009) CC

The Humanitarian Pandemic Preparedness (H2P) Initiative and its many partners have developed ready-to-use training curricula for district- and community-level leaders, and community volunteers and workers in order to minimize morbidity and mortality in the event of an influenza pandemic. The time t... more

External Link

Hepatitis B and liver cancer fact sheet. English.

Cancer Council Victoria (2013) C2

A fact sheet about hepatitis B and its link with liver cancer. It is available in the following languages: English, Arabic, Simplified Chinese, Traditional Chinese, Vietnamese on the website: http://www.hepbhelp.org.au/index.asp?PageID=7

DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines recommended

DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended